PureTech Health plc (PRTC)

27.48 -0.72 (-2.55%) At close: 04:00PM EDT

PureTech Health plc

6 Tide Street
Suite 400
Boston, MA 02210
United States
617 482 2333
https://www.puretechhealth.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 111

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Robert S. Langer Jr., Ph.D.	Co-Founder & Non-Executive Director	145k	N/A	1949
Dr. Eric Elenko Ph.D.	President	N/A	N/A	1973
Dr. David R. Elmaleh Ph.D.	Co-Founder & Senior Advisor	N/A	N/A	1948
Ms. Allison Mead Talbot	Head of Communications & Investor Relations	N/A	N/A	N/A
Mr. Charles Sherwood III, J.D., Ph.D.	General Counsel	N/A	N/A	N/A
Mr. Spencer Ball	Senior Vice President of Human Resources	N/A	N/A	N/A
Ms. Aleksandra Filipovic M.D., Ph.D.	Head of Oncology	N/A	N/A	N/A
Ms. Cheryl Murphy Ph.D.	Head of Grants Management & Strategy	N/A	N/A	N/A
Ms. Anita Terpstra J.D., Ph.D.	Senior VP & Head of Intellectual Property	N/A	N/A	N/A
Mr. Dilip Kodira	Head of Data Science	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Corporate Governance

PureTech Health plc’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.